Active surveillance is a way of monitoring slow-growing prostate cancer, rather than treating it straight away. The aim is to avoid unnecessary treatment, or delay treatment and the possible side-effects.

Last updated: June 2014
To be reviewed: June 2016


  • Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology, March 2013
  • Prostate cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence (NICE). January 2014. Clinical guideline 175
  • Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 2013;64(6):981–87
  • Albertson PC. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncologica 2011;50(1):120–26
  • Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13
  • Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: The PRIAS Study. Eur Urol 2013;63(4):597–603
  • Klotz L. Active Surveillance: The Canadian Experience with an “Inclusive Approach”. J Natl Cancer Inst Monogr 2012;45:234–41
  • Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol 2007;4(12):692–8
  • McVey GP, McPhail S, Fowler S, et al. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 2010;106:1161–64
  • Yacoub JH, Verma S, Moulton JS, et al. Imaging-guided prostate biopsy: conventional and emerging techniques. Radiographics 2012;32(3):819–37
  • Sfoungaristos S, Perimenis P. PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer. Can Urol Assoc J 2012;6(1):46–50
  • Raaijmakers R, de Vries SH, Blijenberg BG, et al. hK2 and free PSA, A prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4–10 ng/ml. Eur Urol 2007;52:1358–64
  • Van As N, Norman A, Woode-Ammissah R, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54(6):1297–305
  • Kazer MW, Psutka SP, Latini DM, Bailey Jr DE. Psychosocial aspects of active surveillance. Curr Opin Urol 2013;23(3):273–77
  • Keyes M, Crook J, Morton G, et al. Treatment options for localized prostate cancer. Canadian Family Physician 2013;59:1269–74
  • Palermo G, Pinto F, Totaro A, et al. High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives. Scandinavian J Urol 2013;47(3):179–87
  • Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr 2012;45:202–6
  • Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876–92
  • Prostate cancer. Follow-up and monitoring. NICE Clinical Knowledge Summaries., last revised January 2011
  • Thompson J, LawrentschukN, FrydenbergM, et al. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Intl 2013;112:6–20
  • Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011;84:3137
  • Dall’Era MA, Cowan JE, Simko J, et al. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Intl 2011;107:1232–37
  • Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes 2013;20(3):204–9
  • Klotz L. Zhang L, Lam A, et al. Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer. J Clin Oncol 2010;28(1):126–31
  • Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: A review of the randomized controlled trial evidence. J Urol 2008;180:2314–22
  • Chan JM, Holick CN, Leitzmann MF, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 2006;17(2):199–208
  • Mishra SI, Scherer RW, Snyder C, et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012
  • Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal and prostate cancer survivorship: a review of the literature. Br J Cancer 2011;105(1):S52–73
  • Richman EL, Kenfield SA, Stampfer MJ, et al. Physical activity after diagnosis and risk of prostate cancer progression: Data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 2011
  • Thorsen L, Courneya KS, Stevinson C, Fossa SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer 2008;16:987–97

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication